Antiretroviral drug resistance and routine therapy, Cameroon

被引：25

作者：

Laurent, C ^{[1
]}

Kouanfack, C

Vergne, L

Tardy, M

Zekeng, L

Noumsi, N

Butel, C

Bourgeois, A

Mpoudi-Ngolé, E

Koulla-Shiro, S

Peeters, M

Delaporte, E

机构：

[1] Inst Rech Dev, UMR 145, Montpellier, France

[2] Cent Hosp, Yaounde, Cameroon

[3] Lab Sante Hyg Mobile, Yaounde, Cameroon

[4] Natl AIDS Program, Yaounde, Cameroon

[5] Mil Hosp, Yaounde, Cameroon

来源：

EMERGING INFECTIOUS DISEASES | 2006年 / 12卷 / 06期

关键词：

D O I：

10.3201/eid1206.050860

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among 128 patients routinely receiving highly active antiretroviral therapy in an HIV/AIDS outpatient clinic in Cameroon, 16.4% had drug resistance after a median of 10 months. Of these, 12.5% had resistance to nucleoside reverse transcriptase inhibitors (NRTIs), 10.2% to non-NRTIs, and 2.3% to protease inhibitors.

引用

页码：1001 / 1004

页数：4

共 50 条

[41] Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
Rui-Hua Kang
Shu-Jia Liang
Yan-Ling Ma
Shu Liang
Lin Xiao
Xin-Hui Zhang
Hong-Yan Lu
Xiao-Qin Xu
Shui-Bin Luo
Xiao-Guang Sun
Lin Chen
Jian-Mei He
Guo-Hui Wu
Ling-Jie Liao
Hui Xing
Yi-Ming Shao
Yu-Hua Ruan
Infectious Diseases of Poverty, 9
[42] The end of the line? A case of drug resistance to third-line antiretroviral therapy
Rossouw, Theresa M.
Hitchcock, Sonia
Botes, Maritte
SOUTHERN AFRICAN JOURNAL OF HIV MEDICINE, 2016, 17 (01)
[43] Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017
Kang, Rui-Hua
Liang, Shu-Jia
Ma, Yan-Ling
Liang, Shu
Xiao, Lin
Zhang, Xin-Hui
Lu, Hong-Yan
Xu, Xiao-Qin
Luo, Shui-Bin
Sun, Xiao-Guang
Chen, Lin
He, Jian-Mei
Wu, Guo-Hui
Liao, Ling-Jie
Xing, Hui
Shao, Yi-Ming
Ruan, Yu-Hua
INFECTIOUS DISEASES OF POVERTY, 2020, 9 (01)
[44] Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection
Menendez-Arias, Luis
Alvarez, Mar
ANTIVIRAL RESEARCH, 2014, 102 : 70 - 86
[45] Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance
Sethi, AK
Celentano, DD
Gange, SJ
Moore, RD
Gallant, JE
CLINICAL INFECTIOUS DISEASES, 2003, 37 (08) : 1112 - 1118
[46] Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance
Habib O. Ramadhani
Charles Muiruri
Venance P. Maro
Balthazar Nyombi
Michael Omondi
Julian B. Mushi
Eileen S. Lirhunde
John A. Bartlett
AIDS and Behavior, 2018, 22 : 1671 - 1678
[47] HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy
Avila-Rios, Santiago
Garcia-Morales, Claudia
Tapia-Trejo, Daniela
Meza, Rita I.
Nunez, Sandra M.
Parham, Leda
Flores, Norma A.
Valladares, Diana
Pineda, Luisa M.
Flores, Dixiana
Motino, Roxana
Umanzor, Victor
Carbajal, Candy
Murillo, Wendy
Lorenzana, Ivette
Palou, Elsa Y.
Reyes-Teran, Gustavo
PLOS ONE, 2015, 10 (11):
[48] Extending antiretroviral therapy to resource-poor settings: implications for drug resistance
Kuritzkes, DR
AIDS, 2004, 18 : S45 - S48
[49] MONITORING OF DRUG RESISTANCE MUTATIONS IN PROVIRAL DNA OF PATIENTS RESPONDING TO ANTIRETROVIRAL THERAPY
Turriziani, O.
Montagna, C.
Falasca, F.
Bucci, M.
Fantauzzi, A.
Esposito, A.
Paola, M.
Mezzaroma, I.
Antonelli, G.
INFECTION, 2011, 39 : S37 - S37
[50] Patient-Initiated Repackaging of Antiretroviral Therapy, Viral Suppression and Drug Resistance
Ramadhani, Habib O.
Muiruri, Charles
Maro, Venance P.
Nyombi, Balthazar
Omondi, Michael
Mushi, Julian B.
Lirhunde, Eileen S.
Bartlett, John A.
AIDS AND BEHAVIOR, 2018, 22 (05) : 1671 - 1678

← 1 2 3 4 5 →